Siltuximab (CNTO 328): a promising option for human malignancies - Wikidata - wikimedia - TriplyDB

Siltuximab (CNTO 328): a promising option for human malignancies

Siltuximab (CNTO 328): a promising option for human malignancies

http://www.wikidata.org/entity/Q28082572

about

Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer From obesity to cancer: a review on proposed mechanisms.Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.Role of interleukin-6 in cancer progression and therapeutic resistance.Tumor-Associated Macrophages as Target for Antitumor Therapy.How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair.Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases.Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

P2860

Q26738539-1B0954FE-E328-4359-8444-2E4A18D883E0 Q30241069-C9B2CD8C-8166-4ECE-80AC-AEFEB0C9F157 Q36878675-4640AC98-B63F-424A-A3AA-52AF5A8359FD Q38853625-87107D9D-0CD6-4E42-B925-FF9CB9328A93 Q39403895-8F550583-5C8E-4E34-906E-680FBD8BFAAB Q47601253-9B86D361-5EC3-4972-B719-9BAAC1C06B3C Q48129259-EACAC478-40FB-49B8-81CD-637EDB712C20 Q51825149-DC8B1EAE-6510-4794-8C3D-7DAE04407121 Q52540247-1AB55420-E26B-413F-B2DB-C2B04C08EE12 Q52560420-CBED198A-629E-40D5-BE83-E4BEFEB542F3 Q55052878-61CA72B9-B509-4F29-B59F-69FFEB5F23CC

P2860

Siltuximab (CNTO 328): a promising option for human malignancies

http://www.wikidata.org/entity/Q28082572

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Siltuximab (CNTO 328): a promising option for human malignancies

@ast

Siltuximab (CNTO 328): a promising option for human malignancies

@en

Siltuximab (CNTO 328): a promising option for human malignancies

@nl

type

label

Siltuximab (CNTO 328): a promising option for human malignancies

@ast

Siltuximab (CNTO 328): a promising option for human malignancies

@en

Siltuximab (CNTO 328): a promising option for human malignancies

@nl

prefLabel

Siltuximab (CNTO 328): a promising option for human malignancies

@ast

Siltuximab (CNTO 328): a promising option for human malignancies

@en

Siltuximab (CNTO 328): a promising option for human malignancies

@nl

P1433

Q28082572-31DB2AD5-7880-48A5-B901-7513CECF4330

P1476

Q28082572-D5AA7246-ED8A-4F10-8BE5-65506545E6C5

P2093

Q28082572-2E8CE2E7-CC53-420E-AEB7-47924816BC82

Q28082572-CF51779A-7372-4440-80EA-B6DAFC4E6701

P275

Q28082572-F447D1A1-97CF-41FE-8782-AA519CC70D99

P2860

Q28082572-047F760B-20F5-4DCD-965D-BB39288EE481

Q28082572-07E64CB6-69DD-4534-AA75-99B3795DBFAF

Q28082572-08436DB0-00F7-4A4C-8A91-FD4567690640

Q28082572-0CAE64F5-D368-44B7-BACE-11D53D53B0CC

Q28082572-11DEE881-6460-4433-AE0D-41EB6452702D

Q28082572-1D4FFF3F-8899-46D6-8617-6A2E2AD7982E

Q28082572-2DB1D1BC-D07C-4297-A71D-5CC46553B3FD

Q28082572-399CF339-AB6E-47C8-B236-395B65C13A92

Q28082572-45F239E8-B754-4FFB-B02E-1A72099E0876

Q28082572-56368BA7-3F42-4D01-B038-3A1A8FFABE9D

P304

Q28082572-7BA4CD6E-242E-4DBE-9EF4-82D4E6FB8CB4

P31

Q28082572-C61D3011-BB87-4810-921B-652BA1F327B9

Q28082572-CDD898E7-8622-44F5-8621-47857884159E

P3181

Q28082572-D8D54501-69FB-420D-8D7F-411602347D4A

P356

Q28082572-7B9D864C-DCE1-4B37-95E3-36197D106C72

P407

Q28082572-D2336019-8885-4804-ADC5-472FE3ED58E6

P478

Q28082572-8E8EC850-006F-4B86-970E-EC3AF5167905

P5008

Q28082572-8DD0BFCB-E13D-42B4-8660-A932CBA38272

P577

Q28082572-0BE149EA-A074-4688-9B1F-31824CE1A595

P698

Q28082572-F22CFD23-371B-4D86-B545-F96193F1BB42

P921

Q28082572-245173E7-FC14-4B0A-8888-3FE2BA47A263

Q28082572-32FFB806-1668-4871-AC50-FA5CC8F9E622

Q28082572-CF3116BB-7EF4-4E18-99B4-E4A8594BD6CF

Q28082572-EB3CAC54-94F0-449C-AD10-38D1CCA94AA0

Q28082572-F8D40511-15FD-4110-BE61-420CDBFCFF26

P932

Q28082572-70F132D3-33A2-4993-8D27-104D7261AEAC

P3181

P356

P1433

Drug Design, Development and Therapy

P1476

Siltuximab (CNTO 328): a promising option for human malignancies

@en

P2093

Bao-An Chen

http://www.w3.org/2001/XMLSchema#string

Runzhe Chen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.

P304

3455-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

378599

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/DDDT.S86438

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26170629

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

P932

4494175

http://www.w3.org/2001/XMLSchema#string